Subarachnoid haemorrhage due to ruptured aneurysms
In development [GID-NG10097] Expected publication date: 21 July 2021
Search results
562 results
-
-
Babies, children and young people's experience of healthcare
In development [GID-NG10119] Expected publication date: 25 August 2021
-
Thyroid cancer: assessment and management
In development [GID-NG10150] Expected publication date: 22 June 2022
-
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management
In development [GID-NG10091] Expected publication date: 21 April 2021
-
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal
In development [GID-NG10141] Expected publication date: 17 November 2021
-
Cardiovascular disease: risk assessment and reduction, including lipid modification
In development [GID-NG10178] Expected publication date: 19 April 2023
-
Type 1 diabetes in adults: diagnosis and management (update)
In development [GID-NG10159] Expected publication date: TBC
-
Postnatal care
In development [GID-NG10070] Expected publication date: 07 April 2021
-
Rehabilitation for Chronic Neurological Disorders Including Traumatic Brain Injury
In development [GID-NG10181] Expected publication date: TBC
-
Type 2 diabetes in adults: management (update)
In development [GID-NG10160] Expected publication date: TBC
-
Diabetes update
In development [GID-NG10152] Expected publication date: TBC
-
Pernicious anaemia
In development [GID-NG10176] Expected publication date: 23 March 2023
-
Reducing sexually transmitted infections
In development [GID-NG10142] Expected publication date: 09 February 2022
-
Osteoarthritis: care and management (update)
In development [GID-NG10127] Expected publication date: 10 August 2022
-
Multiple sclerosis in adults: management
In development [GID-NG10153] Expected publication date: 20 July 2022
-
Conjunctivitis: antimicrobial prescribing
In development [GID-NG10166] Expected publication date: TBC
-
Head injury: assessment and early management
In development [GID-NG10164] Expected publication date: 11 May 2022
-
Shared decision making
In development [GID-NG10120] Expected publication date: 17 June 2021
-
Antenatal care
In development [GID-NG10096] Expected publication date: 11 August 2021
-
Self harm: assessment, management and preventing recurrence
In development [GID-NG10148] Expected publication date: 18 May 2022
-
Epilepsies in children, young people and adults
In development [GID-NG10112] Expected publication date: 09 March 2022
-
Intrapartum care for healthy women and babies (update)
In development [GID-NG10174] Expected publication date: 22 March 2023
-
SACT
In development [GID-NG10184] Expected publication date: TBC
-
Mental wellbeing at work
In development [GID-NG10140] Expected publication date: 15 December 2021
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 17 May 2022
-
Safeguarding adults in care homes
In development [GID-NG10107] Expected publication date: 26 February 2021
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Bulevirtide for treating chronic hepatitis D [ID3732]
In development [GID-TA10652] Expected publication date: 20 October 2021
-
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617
In development [GID-TA10545] Expected publication date: 21 April 2021
-
Andexanet alfa for reversing anticoagulation [ID1101]
In development [GID-TA10440] Expected publication date: 14 April 2021
-
Sapropterin for treating phenylketonuria [ID1475]
In development [GID-TA10378] Expected publication date: 21 April 2021
-
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
In development [GID-TA10561] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Anakinra for treating active Stills disease [ID1463]
In development [GID-TA10392] Expected publication date: TBC
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]
In development [GID-TA10538] Expected publication date: TBC
-
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
-
Erenumab for preventing migraine [ID1188]
In development [GID-TA10302] Expected publication date: TBC
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: TBC
-
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]
In development [GID-TA10701] Expected publication date: 20 July 2022
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: 04 May 2022
-
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]
In development [GID-TA10643] Expected publication date: 16 June 2021
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 17 November 2021
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously treated EGFR-positive metastatic non-small-cell lung cancer [ID3873]
In development [GID-TA10766] Expected publication date: TBC
-
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862]
In development [GID-TA10744] Expected publication date: TBC
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: 05 January 2022
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
In development [GID-TA10122] Expected publication date: TBC
-
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]
In development [GID-TA10725] Expected publication date: TBC
-
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]
In development [GID-TA10417] Expected publication date: 15 September 2021
-
Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer [ID3741]
In development [GID-TA10613] Expected publication date: 13 October 2021
-
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
In development [GID-TA10606] Expected publication date: 08 June 2022